Illumina
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.www.illumina.com
120
MENTIONS
53
EPISODES
43
PODCASTS
Search complete. 120 mentions across 53 episodes found for "Illumina".
Sep 13, 2026
Paul BieniaszGUEST
And they're all consensus sequences as well.
Paul BieniaszGUEST
They're, uh, each one of those hundred is probably generated from a, uh, probably from an Illumina sequencing data set that has a depth of, um, way less than the, the depth-
Vincent RacanielloHOST
Mm
Paul BieniaszGUEST
... that we analyze.
Mike MullHOST
There's a pretty big history of DNA sequencing in San Diego area.
Mike MullHOST
Did you ever like cross paths with the Illumina people or Craig Vettner or any of those people?
Alan DykeGUEST
I didn't know.
Alan DykeGUEST
We did have some engineers left for Illumina, but the company I was working for kind of saw themselves as being able to compete with Illumina.
Alan DykeGUEST
In the end, that didn't work out for them.
Erik AkerHOST
Throw the next one in, Alan.
Chris KirkbrideHOST
And finally, from the UK, a little bit of enforcement action.
Chris KirkbrideHOST
Illumina Cambridge Limited has paid a settlement of just over £7.4 million to HM Revenue and Customs as an alternate.
Chris KirkbrideHOST
an alternative to criminal prosecution following violations of the Russia Regulations 2019.
Chris KirkbrideHOST
According to published HMRC records, between July 2022 and January 2023, the company breached Regulation 25 through its involvement in supplying sanctioned goods between overseas entities within its corporate group for export to Russia and other destinations.
Chris KirkbrideHOST
The case was brought to HMRC's attention via a voluntary disclosure by Illumina, meeting HMRC's criteria for compound settlements offered when breaches are inadvertent or stem from internal control weaknesses rather than intentional evasion.
Chris KirkbrideHOST
Following the investigation, Illumina cooperated fully with authorities, implemented remedial measures and ceased all business involving Russia.
Chris KirkbrideHOST
And finally, to Australia, where the government has launched a four-week consultation period on the Australian sanctions legislation amendment reforms, marking the most significant overhaul of the nation's sanctions framework since the commencement of the Autonomous Sanctions Act 2011.
Chris KirkbrideHOST
Designed to modernize, streamline, and harmonize existing laws, the reforms will be implemented through three proposed bills, including the Cornerstone Autonomous Sanctions Bill 2026, which will replace the 2011 Act, as well as two pieces of subordinate legislation.
Decoding TrollsHOST
Mockers introduced the idea of duty to prevent genocide as a campaigning focus for their work on the...
Decoding TrollsHOST
Illumina stuff.
Decoding TrollsHOST
Neutral is no movement.
Decoding TrollsHOST
And if there's movement in a meme, no emotion moving activity, no charge, no effective charge, then that's fine.
Keith LansfordHOST
Roivant Sciences spiked almost nineteen percent following strong results in a trial testing its lung disease drug.
Keith LansfordHOST
Bloom Energy, Everpure, and Illumina all jumped on news they'd be added to the S&P five hundred index on September twenty-first, Barron's reported.
Keith LansfordHOST
Boston Scientific dropped almost six percent.
Keith LansfordHOST
The company said in a regulatory filing today it's unlikely to meet net sales growth and adjusted earnings guidance for the current quarter and full year, Barron's reported, amid fallout from a late August cyberattack.
Liz DennettGUEST
That technology to have both the turnaround time for DNA sequencing, the price and the ability just to store it in the cloud did not exist probably even five years ago.
Liz DennettGUEST
Our head of platform, Shannon Whitmore, she recently joined us from Illumina, the largest DNA sequencing company.
Liz DennettGUEST
We were so excited to get an Illumina DNA sequencer in-house.
Liz DennettGUEST
Then having her be able to take that raw data, shorten the turnaround time, and integrate it into some of these really nifty and cool emerging algorithms.
Liz DennettGUEST
I think most startups these days are using AI in some form or another.
Derek MooreHOST
I mean, although the rebalances were, were announced, but they would've been known last week, I don't think the quarterly rebalance happens until the morning of the 21st this year.
Derek MooreHOST
By the way, in case you're keeping score at home, it looks like additions, Bloom Energy, Illumina, Everpure, formerly Pure Storage, okay? And they're removing Molson Coors, The Trade Desk, and Builders FirstSource.
Derek MooreHOST
So...
Derek MooreHOST
Oh, S&P 100 changes, that index.
Judy LeBreuxCORRESPONDENT
Shares are surging as much as ten percent, and, uh, the shares are on track for their highest price in two months.
Judy LeBreuxCORRESPONDENT
And again, um, uh, Bloom Energy, along with Illumina, ticker ILMN, and Everpure, ticker P, will be joining the S&P five hundred index before the start of trading on Monday, September twenty-first.
Judy LeBreuxCORRESPONDENT
So a little bit of background about Bloom.
Judy LeBreuxCORRESPONDENT
They make fuel cells that produce electricity from natural gas, and their systems are in high demand due to data center growth.
Nick BanovichGUEST
And, and prote-proteomics can't cheat.
Nick BanovichGUEST
They've gotta measure what's there, and, and that's tough, right? And so I think, you know, the place that I've seen, um, you know, obviously, uh, like a lot of emerging interest is in like plasma proteomics, and I think, you know, the Illumina SOMA scan, uh, technology is, is an example where th-they, they kinda combine the best of both worlds, right? The, the protein is, uh, you know, the, the, the so-- the, the aptamers binding a protein, but then they can still amplify that oligo product on that for sequencing, right? And so you, you are able to do proteomics with a sequencing based readout, which allows you to leverage that, you know, amplifiability, um, piece, right? You know, the, the, the mass spec world is, is still, it's tough, right? Those instruments continue to get more and more sensitive.
Theral TimpsonHOST
Yep.
Nick BanovichGUEST
They're certainly incredibly powerful technologies, but you've got what you've got, you know? The, I, I'm, we, we've got a really great, um, proteomics researcher here at TGen who, who runs our proteomics core, and he's really pushing forward on single-cell proteomics.
David SongGUEST
We definitely feature a lot of companies that are involved in drug discovery.
David SongGUEST
Those are what I would call AI-native drug discovery, as well as enablers of drug discovery like 10X Genomics and Illumina that generate data that allows ultimately datasets to be trained for the frontier models.
David SongGUEST
We can also invest in disruptors from the technology vertical.
David SongGUEST
And then outside of drug discovery, we also are involved in areas like digital health and medical device companies that are poised to benefit in those buckets that we mentioned before.
Neena MishraHOST
So I'm looking at the top holdings in this ETF for Tenex, Genomics, Twist Biosciences.
Neena MishraHOST
I don't know much about these companies.
Neena MishraHOST
Illumina is the third largest.
Neena MishraHOST
I'm familiar with that one.
43 more episodes mention Illumina.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.